Search Terms
Call us today 212-583-0100
ir@enzo.com
Toggle navigation
Home
Corporate
Investor Information
About Us
Officers & Directors
Press Releases
Careers
Therapeutics
About ENZO Therapeutics
Overview
Our Mission
Our Strategy
Partnering
Maps and Directions
Contact Us
Therapeutic Market
Overview
Inflammatory Bowel Disease
Uveitis
HIV
Bone Disorders
Diabetes
Technologies
Immune Regulation
Gene Technology
Cell Signaling Modulation
Pipeline
Overview
Cell Signaling Modulation
Diabetes
Preclinical Studies for Bone Disorders
Immune Regulation
Alequel ™
Optiquel ™
Gene Technology
Stealth Vector™ HGTV43™
Clinical Labs
Life Sciences
Contact
All SEC Filings
Investors
Investors
Overview
News & Events
Overview
Press Releases
IR Calendar
Email Alerts
Company Info
Overview
Management Team
Presentations
Contacts
FAQ
Financial Info
Overview
Financial Results
Income Statement
Balance Sheet
Cash Flow
Stock Data
Quote
Charts
Historical Data
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Board of Directors
Governance Documents
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Filing Type:
View All
10-K
10-K/A
10-K405
10-Q
10-Q/A
11-K
3
3/A
4
4/A
424B3
424B5
5
8-A12B
8-K
8-K/A
ARS
CORRESP
CT ORDER
D
DEF 14A
DEFA14A
DEFC14A
DEFM14A
DEFR14A
DFAN14A
DFRN14A
EFFECT
FWP
NO ACT
NT 10-K
NT 10-Q
NT 11-K
PRE 14A
PREC14A
PREM14A
PRER14A
PRRN14A
RW
S-3
S-3/A
S-3ASR
S-8
S-8 POS
SC 13D
SC 13D/A
SC 13G
SC 13G/A
UPLOAD
Year:
View All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1999
1998
1997
1996
1995
Date
Form
Description
PDF
XBRL
Pages
12/02/21
PRRN14A
Revised preliminary proxy statement filed by non-management
16
12/01/21
10-K/A
Annual report pursuant to Section 13 and 15(d)
Documents
EX-31.1
EX-31.2
15
11/29/21
UPLOAD
SEC-generated letter
Documents
TEXT-EXTRACT
2
11/29/21
10-K/A
Annual report pursuant to Section 13 and 15(d)
Documents
EX-31.1
EX-31.2
15
11/19/21
PREC14A
Preliminary proxy statement in connection with contested solicitations
16
11/15/21
SC 13D/A
Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities
2
11/10/21
4
Statement of changes in beneficial ownership of securities
2
11/10/21
3
Initial statement of beneficial ownership of securities
1
11/09/21
S-8
Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Documents
EX-5.1
EX-23.1
EX-99.1
EX-99.2
11
10/28/21
SC 13D/A
Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities
11
Previous
1…
11
12
13
14
15
16
17
18
19
20
…110
Next
Email Alerts
Tear Sheet
Contacts
RSS News Feed